Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Robotech strategy - August 2023

  • 11 September 2023 (5 min read)

Corporate earnings results have been generally good for the strategy

  • Macro uncertainty weighed on global equity markets and investor sentiment
  • 75%1 of our companies reported earnings better than analysts forecast for Q2 2023
  • Weakness in the semiconductors space after strong year-to-date performance

What’s happening?

Global equity markets gave back some of their year-to-date gains in the month of August with the MSCI All Country World Index declining +2.8%2 in USD terms. Macro uncertainty weighed on investor sentiment during the period and the Robotech strategy lagged the broader market during the month, with some more notable weakness seen in its semiconductor and MedTech holdings.

Corporate earnings results have been generally good for the strategy with 75% of the holdings in the strategy beating earnings expectations in the current earnings season.  This contrasts to the MSCI All Country World Index where 52% of companies beat their earnings expectations (source Bloomberg as of 31/08/2023).  However, company outlooks have been framed with some caution with mixed trends seen in industrial activity and weaker conditions in China.  Towards the end of August, the latest Chinese manufacturing PMI reading (Purchasing Managers Index) suggested signs of stabilisation in the manufacturing sector in China.  However we would look to see more data points to confirm this trend before turning more optimistic for a recovery.

Portfolio positioning and performance

Results from Nvidia were very strong with record datacentre revenue driven by exceptional demand for chips to support Generative AI and Large Language Models.  Whilst the share price returns for Nvidia have been very significant at 238% year to date (in USD to 31/08/23), consensus earnings expectations for 2024 have approximately tripled which has supported valuations.  Investors are increasingly focussed on Nvidia’s ability to scale production at its manufacturing partners to meet these surging orders whilst also questioning the ultimate sustainability of this demand.  Elsewhere in the semiconductor space, after a period of strength, we saw weakness across a number of our holdings.  This appears to have been driven more by macro-economic concerns rather than fundamentals in these businesses. 

We saw positive performance from Autodesk, a US software company focused on the design, construction and engineering end markets. Despite macro concerns, the company delivered robust results thanks to the resilience of its subscription model and solid execution.

Our MedTech holdings were weaker during the period, despite having a solid earnings season.  The increased investor interest in GLP-13 ’s (weight loss drugs, principally from Eli Lilly and Novo Nordisk) weighed on sentiment as investors seek to understand potential implications of wider adoption of these drugs on other treatments & procedures.  Intuitive Surgical was impacted on concerns that success in weight loss from these drugs could impact the number of bariatric procedures performed or delay patients procedures as they try weight loss medications first.  We would suggest that the impacts are likely more limited, with Bariatric surgery only representing 2-3% of Intuitive Surgical’s annual procedure volumes.  We would note that when they reported results, Intuitive Surgical upgraded their expectations for procedure volumes to be 20-22%4 above last year’s volumes indicating that growth should be robust even if there is a slowdown in Bariatric procedures.  There were similar concerns that widespread adoption of these drugs could mean that in the long-term there are fewer diabetic patients, limiting the addressable market for companies like Dexcom.  We anticipate that any impacts for the foreseeable future would be minor and continue to see Continuous Glucose Monitoring as a significant growth opportunity.

We continued to build our position in Applied Materials, a US semiconductor equipment vendor which we added to the portfolio in June.  Applied Materials is seeing healthy demand for its machines on robust Capex5 trends.

We reduced our positions in semiconductor companies Silicon Labs and Qualcomm.  Silicon Labs is focussed on Internet of Things chips and is currently seeing customer demand weaker as more cost conscious consumers appear to be reducing some discretionary spend on household electronics.  For Qualcomm, we see better opportunities elsewhere in the semiconductor industry with strong trends in areas outside of mobile.


Inflationary pressures across the major economies of the world continue to soften, whilst economic indicators have been resilient, particularly the US, further pushing out the risk of an imminent recession.  In China, government policymakers struck a more positive tone on potential stimulus measures as the economy has experienced a slower than expected recovery post Covid reopening. Chinese Industrial Activity continues to be a weak spot globally and trends in the region have not rebounded to the extent anticipated post the removal of COVID restrictions at the start of 2023. Rising government incentives from other countries, attempting to reshore manufacturing and invest more in home markets, is acting as a further headwind and at the expense of potential investments in China.

The labour market continues to be tight in many areas where continued labour shortages present a real challenge for businesses. For instance, in the manufacturing space or warehousing space, we see fewer workers – particularly younger demographics – that are willing to do these kinds of jobs, given the nature of the roles and the salary. As a result – facing labour inflation and labour shortages – companies are increasingly incorporating Technology and Automation in their processes to increase efficiency and productivity with their existing/shrinking workforce. In simple terms, we anticipate that labour shortages and wage inflation are substantial drivers of automation demand over the next few years. As labour costs go up, the payback periods become quicker from introducing automation, meaning that more and more areas are considered for automation.

The US is trying to reinvigorate its domestic manufacturing via infrastructure spend and capital expenditures (CAPEX). This is important politically as its US Jobs, important geopolitically as it keeps US intellectual property within the US and important for supply chain as its secure stock within the country after the disruption witnessed post-COVID. Government support has evolved over the past few years, whether it be the Trump Administration – with tariffs in the US China trade war – or more recently with the Biden administration and the CHIPS Act signed to ramp up and ‘reshore’ US technology such as domestic semiconductor manufacturing. US president Biden also passed the Inflation Reduction Act (IRA) allocating a lot of spend for more domestic US manufacturing, focussed on key technologies. As a result of tariffs, incentives and reducing the risk of supply chain issues, companies are investing again in the US and this comes with technological sophistication, robotics and automation.

  • Qmxvb21iZXJnIGFzIG9mIDMxLzA4LzIwMjM=
  • Qmxvb21iZXJnIGluIFVTRCBhcyBvZiAzMS8wOC8yMDIz
  • R0xQLTEmbmJzcDs6IEdsdWNhZ29uLUxpa2UgUGVwdGlkZS0x
  • SW50dWl0aXZlIEFubm91bmNlcyBTZWNvbmQgUXVhcnRlciBFYXJuaW5ncywgMjAvMDcvMjAyMw==
  • Q0FQRVgmbmJzcDs6IENhcGl0YWwgRXhwZW5kaXR1cmVz

Stock/company examples are for explanatory/illustrative purposes only.  They should not be viewed as investment advice or a recommendation from AXA IM. These examples do not represent all of the securities purchased, sold or recommended for the client’s accounts. No representation is made that these were or will be profitable.

No assurance can be given that the Robotech Strategy will be successful. Investors can lose some or all of their capital invested. The Robotech strategy is subject to risks including; Equity; Emerging markets; Investments in specific sectors or asset classes; Global investments; Investments in small and/or micro capitalisation universe; ESG.

Download the full monthly perspective
Download report (240.81 KB)


Investing in automation and robotics - How are companies capitalising on robotics – and what does this mean for investors?

Find out more

Visit the Fund centre

AXA WF Robotech strategy

The Sub-Fund seeks to provide long-term capital growth, measured in USD, from a portfolio of listed equity and equity related securities, in line with a socially responsible investment (SRI) approach.

View funds


    Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in a European Union country by notification to its authority of supervision in accordance with European passport rules. In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English here). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The European online dispute resolution platform allows you to enter a complaint form (by clicking here) and informs you, depending on your jurisdiction, about your means of redress (by clicking here).

    Issued in the U.K. by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. 

    Are you an IFA or other Professional Investor ?

    Are you a financial advisor, institutional, or other professional investor?

    This section is for professional investors only. You need to confirm that you have the required investment knowledge and experience to view this content. This includes understanding the risks associated with investment products, and any other required qualifications according to the rules of your jurisdiction.